This trial is conducted in Europe. The aim of this clinical trial is to investigate if two identical formulations of NN1250 (insulin degludec, IDeg) have the same level of drug exposure to the body.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
26
Each subject will be allocated to 2 single doses of trial product on 2 separate visits: One injection with formulation 1 and and one injection with formulation 2). Injected subcutaneously (under the skin).
Each subject will be allocated to 2 single doses of trial product on 2 separate visits: One injection with formulation 1 and and one injection with formulation 2). Injected subcutaneously (under the skin).
Unnamed facility
Neuss, Germany
Area under the Insulin Degludec concentration-time curve
Time frame: From 0 to 120 hours after single-dose
Maximum observed Insulin Degludec concentration
Time frame: From 0 to 120 hours after single-dose
Area under the Insulin Degludec concentration-time curve
Time frame: From 0 to infinity after single-dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.